Harish Chowdary Gorrepati/LinkedIn
Sep 1, 2026, 15:09
Harish Chowdary Gorrepati: The HALT Paradox After TAV
Harish Chowdary Gorrepati, Interventional Cardiologist at Sri Venkateswara Institute of Medical Sciences (SVIMS), Tirupati, Fellow at Heart Center UMC, shared a post on LinkedIn:
“NOTION-4 Trial | TAVR and Antithrombotic Therapy.
Short-term DOAC after TAVR significantly reduced HALT at 3 months (31.8 percent – 12.1 percent), but this benefit was not sustained at 12 months (32.2 percent versus 28.3 percent; P=0.54).
Importantly, bleeding/clinical events were numerically higher with the DOAC strategy.
Key message: Reducing leaflet thrombosis on CT does not necessarily translate into better clinical outcomes.
SAPT remains the preferred strategy for patients without another indication for oral anticoagulation.”
Stay updated with Hemostasis Today.
-
Oct 18, 2026, 02:43Priya Sriskandarajah: Diagnosis and Management of PV and JAK2-Unmutated Erythrocytosis
-
Oct 18, 2026, 02:41C. Michael Gibson: A Meta-Analysis of DOACs and DAPT After Left Atrial Appendage Closure
-
Oct 18, 2026, 02:27What Hematologists Should Remember About the Person Behind the Platelet Count – ASH
-
Oct 18, 2026, 01:44Marta Velia Antonini: How to Deliver CRRT during ECMO?
-
Oct 18, 2026, 01:19Aamir Saeed: Anticoagulation, Cirrhosis, and Other Risk Factors for Post-ERCP Bleeding
-
Oct 18, 2026, 00:33Elad Asher: Does Opening the Clot Change How a Patient Feels Three Months Later?
-
Oct 18, 2026, 00:22Richa Sharma: Evaluating Heterogeneity in Anticoagulation Treatment Effects in Cryptogenic Stroke
-
Oct 18, 2026, 00:07Irem Karaman Sebin: The Evidence Favoring Warfarin in High-Risk Antiphospholipid Syndrome
-
Oct 18, 2026, 00:07Emma Stevens: Lighting Up Buildings in Red and Blue for World Thrombosis Day